Additionally, the anti‐atherosclerosis action of LAV‐BPIFB4 gene therapy was attributed to a mechanism involving the stromal cell‐derived factor‐1 (SDF‐1) and related CXCR4 receptor.8 The gene discussed is CXCL12; the disease is atherosclerosis.